Loading…
ZBIO
Zenas BioPharma, Inc.
NASDAQ· Healthcare· Biotechnology
$31.27-4.14%
Key metrics
- Market cap
- $2.04B
- P/E
- —
- Forward P/E
- —
- P/B
- 8.0x
- Dividend yield
- —
- EPS
- -$9.63
- ROE
- -199.04%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $44.60
- 52-week low
- $13.50
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
- 167
- Waltham, United States
Company description provided by Yahoo Finance.